Silo Pharma (SILO) Share-based Compensation (2010 - 2026)
Silo Pharma (SILO) posted Share-based Compensation of $52836.0 for Q1 2026, up 1.01% sequentially from $52309.0 in Q4 2025, and up 537.73% YoY from $8285.0 in Q1 2025.
Silo Pharma (SILO) Share-based Compensation (2010 - 2026) Analysis & Trends
Silo Pharma has reported Share-based Compensation for 8 years, with the latest figure at $52836.0 in Q1 2026.
- Quarterly Share-based Compensation rose 537.73% year-over-year to $52836.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52836.0 (up 54.0% YoY) and the FY2025 annual result came in at $117021.0, changed N/A from the prior year.
- Share-based Compensation advanced to $52836.0 in Q1 2026 per SILO's latest filing, from $52309.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $137277.0 in Q3 2025 and troughed at -$18078.0 in Q2 2024.
- A 5-year average of $26551.0 and a median of $16725.5 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 526.67% in 2024, then surged 1066.23% in 2025.
- Over 5 years, Share-based Compensation stood at $39175.0 in 2022, then sank by 96.39% to $1414.0 in 2023, then jumped by 732.46% to $11771.0 in 2024, then jumped by 344.39% to $52309.0 in 2025, then advanced by 1.01% to $52836.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $52836.0, $52309.0, and $137277.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | - |
| 10 | Silo Pharma | 3.08 Mn | 3.08 Mn | - | 13,662.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,662.00 |
| Jun 30, 2026 | 13,662.00 |
| Mar 31, 2026 | 52,836.00 |
| Mar 31, 2026 | 52,836.00 |
| Dec 31, 2025 | 52,309.00 |
| Dec 31, 2025 | 52,309.00 |
| Sep 30, 2025 | 137,277.00 |
| Sep 30, 2025 | 137,277.00 |
| Jun 30, 2025 | -1,140.00 |
| Jun 30, 2025 | -1,140.00 |
| Mar 31, 2025 | 8,285.00 |
| Mar 31, 2025 | 8,285.00 |
| Sep 30, 2024 | 11,771.00 |
| Sep 30, 2024 | 11,771.00 |
| Jun 30, 2024 | -18,078.00 |
| Jun 30, 2024 | -18,078.00 |
| Mar 31, 2024 | 32,331.00 |
| Mar 31, 2024 | 32,331.00 |
| Dec 31, 2023 | 1,414.00 |
| Dec 31, 2023 | 1,414.00 |